Concerta LP 36 mg , 36 mg/24 hr extended release
Concerta LP 36 mg is an expensive drug used to treat attention-deficit hyperactivity disorder (ADHD). It is also used to treat narcolepsy. This drug is slightly more popular than comparable drugs. It is available in brand and generic versions.
Methylphenidate is readily absorbed. Following oral administration of CONCERTA to adults, the drug overcoat dissolves and plasma methylphenidate concentrations increase rapidly reaching an initial maximum at about 1 to 2 hours. The methylphenidate contained in two internal drug layers is gradually released over the next few hours. Peak plasma concentrations are achieved at about 6 to 8 hours after which plasma levels of methylphenidate gradually decrease. CONCERTA once daily minimises the fluctuations between peak and trough concentrations associated with immediate-release methylphenidate three times daily. The extent of absorption of CONCERTA once daily is generally comparable to conventional immediate release preparations given three times daily.
Plasma methylphenidate concentrations in adults decline biexponentially following oral administration. The terminal plasma half-life of methylphenidate in adults following oral administration of CONCERTA was approximately 3.5 hours.
In humans, methylphenidate is metabolised primarily by de-esterification to -phenyl-piperidine acetic acid (PPAA) which has little or no pharmacologic activity. In adults the metabolism of CONCERTA once daily, as evaluated by metabolism to PPAA, is similar to that of methylphenidate three times daily. The metabolism of single and repeated once daily doses of CONCERTA is similar.